NCT01275209 - Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Follicular Lymphoma

Interventions

DRUG

HCD122

Trial Locations (12)

Novartis Investigative Site, Leuven

Novartis Investigative Site, Prahran

Novartis Investigative Site, Ghent

Novartis Investigative Site, Torino

Duke University Medical Center Duke Hem & Onc, Durham

Novartis Investigative Site, Madrid

Sarah Cannon Research Institute SC - 2, Chattanooga

Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (6), Detroit

Novartis Investigative Site, Paris

Dana Farber Cancer Institute SC-5, Boston

Novartis Investigative Site, Toronto

Novartis Investigative Site, Barcelona